12:00 AM
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elagolix: Phase II data

Follow-up data from the Phase II PETAL trial showed that elagolix sustained safety and efficacy after treatment was stopped. Patients received 150 mg once-daily elagolix, 75 mg twice-daily elagolix or Depo-subQ provera 104 for 24 weeks, followed by 24 weeks of no treatment. At week 48, elagolix patients had...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >